Re: Farmas USA
ARNA
Upgrades:
Needham: 60$
Citi: 62
JMP: 79
Artículo SA:
Etrasimod Phase 2 data showed outstanding efficacy and safety.
Celgene’s Ozanimod is in a serious competitive threat.
Even half of Ozanimod’s value means $175/share in Arena terms.
Analysts issued upgrades across the board.
Comparing these results with Celgene’s (NASDAQ: CELG) Ozanimod, Etrasimod fairs much better on all fronts including:
- Three Component Partial Mayo Clinic Score
- Endoscopic Improvement
- Clinical Remissions
- Lymphocyte bounce recovery time clearly makes Etrasimod the better choice
The clinical Remission data is especially significant since it’s an endpoint that has been historically used in Phase 3 registrational trials. Etrasimod did phenomenally well, compared to Ozanimod:
- Etrasimod: [24.5% in the Etrasimod 2 mg group compared to 6.0% for the placebo group (p = 0.004)]
- Ozanimod: [16% in the Ozanimod 1 mg group compared to 6% for the placebo group (p = 0.048)]
As a reminder to the readers, Celgene bought Receptos in 2015 for its ownership of Ozanimod at a price tag of $7.2b, which translates to around $175/share in Arena’s terms.
https://seekingalpha.com/article/4158032-arena-star-acquisition-target-post-positive-trial-results
«Después de nada, o después de todo/ supe que todo no era más que nada.»